Collaborative Study for the calibration and commutability assessment of the proposed 1

biological activity of TNF- α. To achieve the aims of the study participants are requested to use a fixed dose of the TNF- α IS. The concentration used should provide a biological

The potencies of the study samples A, C, D, E and F were also calculated relative to sample B, using the overall geometric mean potency for B of 9.52 x 10 4 IU/ml (Table 4,

Based on the results obtained from the ribose assays performed by 11 participants in this collaborative study and from the stability study performed by lab 7, we

Reported laboratory mean potency estimates (Log 10 IU/mL) for samples 7 and 8, their mean potency estimates relative to the current HAV International Standard sample 1 (00/562) and

The means of folate content in each preparation for the different assay methods are shown in Table 4, along with the overall means and the inter-laboratory (i.e. between

a) To assess the suitability of ampouled preparations of Infliximab to serve as the 1st WHO IS for anti-human TNF (Infliximab) by assaying their biological activity in a

assays were analysed as described for the main collaborative study, and the potencies of the stored samples were expressed relative to the freshly reconstituted

The mean overall potency relative to the current IS (coded 86/504) for duplicates A and B of the candidate standard derived using data from all assays were 201 and 203 IU while